Compare MakeMyTrip Ltd (MMYT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Sana Biotechnology Inc — how do they compare? MakeMyTrip Ltd trades at $56.43 (market cap $5.05B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: MakeMyTrip Ltd is far larger — about 5.8× Sana Biotechnology Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| MMYT | SANA | |
|---|---|---|
Market Cap | $5.05B | $873.84M |
Sector | Technology | Health |
52-Week High | $103.21 | $5.92 |
52-Week Low | $36.30 | $2.68 |
Enterprise Value | $5.69B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal despite recent weakness. The company shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.25 beating expectations of $0.17. Revenue reached $978.34 million in 2025 with a 73.77% gross margin, though 2026 projections indicate margin compression. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target.
The stock presents a growth opportunity with strong operational performance but faces risks from travel disruptions and rising debt levels. While current valuation metrics appear elevated (P/E 147.78), the company's market leadership in Indian online travel and consistent execution support the bullish case. Key risks include competitive pressures and macroeconomic sensitivity to travel demand.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
